Study of Patient Admitted For Portal Hypertension At Tertiary Care Hospital
Study of Patient Admitted For Portal Hypertension At Tertiary Care Hospital
DOI:
https://doi.org/10.70284/njirm.v8i3.1254Keywords:
Devascularisation , Portal HypertensionAbstract
Introduction: The portal venous system is the main vascular system supplying another organ, the liver. Noncirrhotic portal hypertension (NCPH) is a heterogeneous group of vascular diseases that lead to portal hypertension (PH) with normal or mildly elevated hepatic venous pressure gradient and preserved liver synthetic function. Surgery in NCPH aims to bypass the portal resistance site by creating portoportal or, more commonly, portosystemic shunts (PSS); when not feasible, techniques that involve esophagogastric devascularization (direct ligation of varices or esophageal transection), with or without an associated splenectomy may be undertaken. Methods: Prospective interventional study consisted of 30 patients with portal hypertension was carried out at Department of Surgery, New Civil Hospital, Surat during December-15 to January-16. Results: Male female ratio was 7:3 and majority among age group of 31 to 40 years. All 30 patients came with complaint of haemetemesis and abdominal lump in the form of splenomegaly. All patients were having oesophageal varices and features of hypersplenism. No pateint was having ascitis. Portal vein was >12mm in diameter and there was centripetal blood flow in all patients. Mean operative time duration was 170 min. Mean duration of hospital stay was 7 days. Conclusion: After splenectomy with devascularisation surgery, blood counts were increased and patients had relief from symptom of haemetemesis which was assessed 1month, 3 months and 6 months after Operation. [Bina V NJIRM 2017; 8(3):89-92]
References
2. Genecin P, Groszmann RJ. The biology of portal hypertension. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. The Liver: Biology and Pathobiology. New York: Raven press, Ltd.; 1994. p. 1327-1341.
3. Bosch J, Garcia-Pagan JC, Feu F, Rodes J. Portal hypertension. Clinical pathobiology. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. The Liver: Biology and Pathobiology. New York: Raven press, Ltd.; 1994. p. 1343-1355.
4. Conn HO, Groszmann RJ. Portal hypertension: measurement and manifestation. Viewpoints on digestive diseases 1982;14(1):1-4.
5. Viallet A, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975;69(6):1297-300.
6. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-424.
7. Lebrec D, De Fleury P, Rueff B, Nahum H, Benhamou JP. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 1980;79:1139-1144.
8. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first bleeding from a first variceal hemorrhage. Gastroenterology 1990;99:1401-1407.9. Reynolds JD, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. Am J Med 1970;49:649-657.
10. Rossle M, Haag K, Blum HE. The transjugular intrahepatic portosystemic stent-shunt: a review of the literature and own experiences. J Gastroenterol Hepatol 1996;11(3):293-8.
11. Patch D, Armonis A, Sabin C, Christopoulou K, Greenslade L, McCormick A, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 1999;44:264-269.
